PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF
申请人:ALS Mountain Llc
公开号:EP2983473A2
公开(公告)日:2016-02-17
NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS
申请人:Chen Chien-Hung
公开号:US20120183600A1
公开(公告)日:2012-07-19
The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.
[EN] PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UN ACTIVATEUR D'AMPK ET UN AGENT SÉROTONINERGIQUE ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
申请人:ALS MOUNTAIN LLC
公开号:WO2014144130A2
公开(公告)日:2014-09-18
The present invention is based on the unexpected discovery that a combination of certain known drugs exhibits synergistic effects in treating metabolic syndrome and various other diseases. In particular, the invention comprises a pharmaceutical composition comprising: (1) a therapeutically effective quantity of a first agent that is an AMPK activator; and (2) a therapeutically effective quantity of a second agent that possesses or maintains serotonin activity. A preferred composition comprises metformin hydrochloride and melatonin. The invention further comprises methods for the use of these compositions for the treatment of metabolic syndrome, hyperproliferative diseases including cancer, and other diseases and conditions.
<scp>l</scp>-2‘,3‘-Didehydro-2‘,3‘-dideoxy-3‘-fluoronucleosides: Synthesis, Anti-HIV Activity, Chemical and Enzymatic Stability, and Mechanism of Resistance
作者:Youhoon Chong、Giuseppe Gumina、Judy S. Mathew、Raymond F. Schinazi、Chung K. Chu
DOI:10.1021/jm0300274
日期:2003.7.1
the L-3',3'-difluoro-2',3'-dideoxy nucleoside series, cytidine 16 and 5-fluorocytidine 18 analogues showed modest antiviralactivity (EC(50) 11.5 and 8.8 microM, respectively) when evaluated against HIV-1 in human peripheral blood mononuclear (PBM) cells. In the 2',3'-unsaturated series, L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine 24 and 5-fluorocytidine 26 showed highly potent antiviral activity